TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05252416
Drug: BLU-222
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04192435
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
Study: NCT06395012
Drug: LY3985297
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either IV or SC.
Study: NCT06395012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either IV or SC.
Study: NCT06283550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05889871
Drug: Standard endocrine therapy plus Apatinib
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard endocrine therapy plus Apatinib
Study: NCT04886739
Drug: CGB-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT04886739
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT05540288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Study: NCT05501678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo given orally
Study: NCT05977140
Drug: CDI-988
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 3CL protease inhibitor
Study: NCT05977140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05966480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05623839
Drug: LY3305677
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05623839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05748197
Drug: Conditioning chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
Study: NCT04335032
Drug: Eicosapentaenoic acid gastro-resistant capsules
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: same as in arm/group description
Study: NCT04335032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same as in arm/group description
Study: NCT05960942
Drug: propofol-sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
Study: NCT05092347
Drug: Vonsetamig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT06802081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
Study: NCT05083481
Drug: ASP1570
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05083481
Drug: Trifluridine + Tipiracil
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT06639958
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06503016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution of NaCl 0.9%
Study: NCT03899636
Drug: Modified FOLFIRINOX Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
Study: NCT06363851
Drug: Kylo-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06363851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05592262
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: On an empty stomach - after meals
Study: NCT05592262
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: After meals - on an empty stomach
Study: NCT05136287
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are included after GLP1 agonists prescription , at the first dispensation
Study: NCT04487860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT06354712
Drug: N-Acetyl-Cysteine with Institutional standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
Study: NCT06354712
Drug: Institutional standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine Mouthwash
Study: NCT04622293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo encapsulated to look the same as the experimental drug will be given to the control group.
Study: NCT05670054
Drug: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Study: NCT05244304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not active drug
Study: NCT05393388
Drug: [18F]AV-1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
Study: NCT06401083
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/kg caffeine-citrate before the planned extubation.
Study: NCT06198426
Drug: IBI3004
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Study: NCT05583812
Drug: FB2001 for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB2001 once or twice daily inhalation
Study: NCT05583812
Drug: FB2001 for inhalation placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB2001 placebo once or twice daily inhalation
Study: NCT06058156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06536491
Drug: EC-104 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT06319963
Drug: Two IM injections Lenti-HPV-07
Approvals — FDA: no, EMA: no, PMDA: no
Description: two Lenti-HPV-07 intramuscular injections one month apart
Study: NCT06319963
Drug: One IM injection Lenti-HPV-07
Normalized name: Gel-One Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
Study: NCT05719376
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
Study: NCT04873583
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)
Study: NCT05960864
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop
Study: NCT05868109
Drug: inhaled nitric oxide (iNO)
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
Study: NCT05868109
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
Study: NCT06203275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
Study: NCT06253130
Drug: IMP1734
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP1 selective inhibitor
Study: NCT05735483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04799158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally via capsules
Study: NCT06559163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04680052
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered IV for 12 cycles
Study: NCT06189508
Drug: NXT007
Approvals — FDA: no, EMA: no, PMDA: no
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
Study: NCT04620603
Drug: Standard-of-Care Immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
Study: NCT05218096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT05238493
Drug: VEL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
Study: NCT05238493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
Study: NCT05335499
Drug: TAS5315 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period: oral administration for 12 weeks, QD
Study: NCT05335499
Drug: TAS5315 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period: oral administration for 12 weeks, QD
Study: NCT05335499
Drug: TAS5315 Dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period: oral administration for 12 weeks, QD
Study: NCT05335499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD
Study: NCT04636814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
Study: NCT06089837
Drug: EC5026 oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)
Study: NCT06089837
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
Study: NCT06014437
Drug: PLCL/Fg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
Study: NCT06014437
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
Study: NCT05193409
Drug: 225 mg BNC210
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg BNC210
Study: NCT05193409
Drug: 675 mg BNC210
Approvals — FDA: no, EMA: no, PMDA: no
Description: 675 mg BNC210
Study: NCT05193409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05485155
Drug: Alpha-proteinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.
Study: NCT05709249
Drug: placebo (XLJDOD mimetic agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.
Study: NCT06496919
Drug: Recombinant Mutant Human Tumor Necrosis Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
Study: NCT05682495
Drug: ARM A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
Study: NCT05682495
Drug: ARM B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
Study: NCT05682495
Drug: ARM C
Normalized name: Forearm Crutch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
Study: NCT05682495
Drug: ARM D
Normalized name: Clever Choice BP Monitor/Arm Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
Study: NCT05682495
Drug: ARM E
Normalized name: Clever Choice Upper Arm Elite Blood Pressure Monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
Study: NCT05682495
Drug: ARM F
Normalized name: Scheinpharm FLUoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
Study: NCT05427253
Drug: C106 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
Study: NCT05427253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for C106 solution
Study: NCT05241821
Drug: Thrombolytic Agent
Normalized name: Thrombolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug aimed to dissolve thrombus affecting the cerebral circulation
Study: NCT06412497
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines.
Study: NCT06204809
Drug: PGN-EDODM1 for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PGN-EDODM1 by intravenous (IV) infusion
Study: NCT05822544
Drug: TLC-6740 Oral Solution
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of TLC-6740
Study: NCT05822544
Drug: TLC-6740 Tablet
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of TLC-6740
Study: NCT05822544
Drug: Drug Metabolizing Enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of omeprazole, voriconazole, or itraconazole
Study: NCT05838729
Drug: RiMO-301
Normalized name: Rimoxyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions.
Study: NCT05437575
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl citrate 10mcg/ml packaged in pre-filled syringe
Study: NCT05797610
Drug: sefaxersen (RO7434656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sefaxersen (RO7434656) will be administered subcutaneously per schedule as specified.
Study: NCT05797610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously per schedule as specified.
Study: NCT05071937
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
Study: NCT04450953
Drug: Eplerenone 50mg/day (cross over design)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50mg/day for 6 months followed
Study: NCT06060665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06798662
Drug: Drug (famciclovir and gabapentin)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive famciclovir and gabapentin. All participants will receive standard antiviral therapy with famciclovir 500 mg orally three times daily for 7 days. Gabapentin will be initiated at a typical starting dose of 300 mg per day, administered in three divided doses. The dosage may be gradually increased, as needed and tolerated, up to a maximum dose of 1800 mg per day.
Study: NCT04948788
Drug: SHR1459 ；YY-20394
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR1459 plus YY-20394
Study: NCT06426485
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once a day
Study: NCT05297201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
Study: NCT04628767
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given Iv
Study: NCT04628767
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06028074
Drug: GIM122
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIM-122 administered IV once every 3 weeks or every 2 weeks
Study: NCT05189457
Drug: New Hormonal Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
Study: NCT05351502
Drug: Nitric Oxide 25,000 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of 25,000 gNO
Study: NCT05351502
Drug: Nitric Oxide 50,000 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of 50000 gNO
Study: NCT05351502
Drug: Nitric Oxide 100,000 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of 100,000 gNO